The increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide are the major factors driving the growth of this market.

This report segments this Antinuclear Antibody Testing Market based on products, diseases, techniques, end users, and regions. In the products market, the assay kits and reagents segment is expected to account for the largest share. This segment is also expected to grow at the highest CAGR during the forecast period due to the growth in the number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide.

Based on techniques, the Antinuclear Antibody Testing Market is segmented into three broad segment, namely, enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market owing to expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.

The end-user segments in this market include clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share in 2016, primarily due to the rising healthcare spending which has resulted in a growth in use of ANA testing products in hospitals. Based on region, the global Antinuclear Antibody Testing Market is segmented into North America, Europe, Asia, and the rest of the world. North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as rising geriatric population and increasing prevalence of autoimmune diseases.

Key players in the Antinuclear Antibody Testing Market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).